Summary

Healthcare Contract Manufacturing Market Summary

The global healthcare contract manufacturing market size was estimated at USD 213.06 billion in 2024 and is projected to reach USD 566.16 billion by 2033, growing at a CAGR of 11.7% from 2025 to 2033. The market is driven by the expanding biologics and biosimilars market, increasing regulatory complexity, and the commercial success of biologics for clinical use.

Contract manufacturers with established biologics platforms support pharmaceutical companies in scaling up complex biologic drug manufacturing, including monoclonal antibodies, vaccines, and cell and gene therapies. As patents expire for blockbuster biologics, biosimilars gain prominence, creating outsourcing opportunities for CMOs/CDMOs with flexible capacity. Their expertise in process development, large-scale production, and quality management positions them as critical partners in meeting rising global demand for biologics and biosimilars, significantly driving the healthcare contract manufacturing market’s growth.

Furthermore, organizations such as the FDA, EMA, and WHO have strict and changing regulations for the global healthcare industry. A substantial investment in data integrity, quality assurance, and Good Manufacturing Practices (GMP) is necessary to meet manufacturing compliance. Many businesses, particularly new biopharma and medtech enterprises lack the internal infrastructure and knowledge necessary to meet these criteria. A dependable option is provided by contract manufacturers with proven compliance frameworks, regulatory approvals, and inspection histories. Businesses reduce risks, prevent expensive delays, and guarantee quicker market access through outsourcing. Global demand for contract manufacturing partnerships is significantly fueled by the growing complexity of regulations.

The need for pharmaceutical medications and medical equipment is being driven by the increasing frequency of noninvasive surgical operations. OEMs are progressively outsourcing non-core manufacturing tasks in order to handle this growth, which allows for lower labor costs, better capital utilization, increased productivity, and shorter lead times. For pharma companies of all sizes, outsourcing has become a cost-effective strategy, particularly as fixed costs for biologics manufacturing-representing nearly 60-70% of the Cost of Goods Sold (COGS)-remain unavoidable even during idle production periods. This makes outsourcing an economically viable option to balance efficiency, scalability, and cost management in a competitive healthcare landscape.

Furthermore, the adoption of multi-product facilities for biologics manufacturing has demonstrated both economic efficiency and safety, as risks of product carryover are negligible, thereby driving market growth. However, rapid supply chain adaptation is a difficulty for the heavily regulated medical device business. Although the FDA actively monitors and responds to shortages, U.S. manufacturers are not required to notify the agency of any actual or prospective shortages. Aluminum, integrated circuits, lithium-ion batteries, and specialty parts such as platinum, pneumatic fittings, and black body radiation sources are among the items in short supply. According to Medical Product Outsourcing, outsourcing should result in lower costs and a quicker time to market, which is expected to support the expansion of the healthcare CRO market.

Global Healthcare Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare contract manufacturing market report based on type, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Medical Devices
o Service
o Accessories manufacturing
o Assembly manufacturing
o Component manufacturing
o Device manufacturing
o Therapeutic Area
o Oncology
o Infectious Diseases
o Neurological Disorders
o Cardiovascular Disease
o Metabolic Disorders
o Autoimmune Diseases
o Respiratory Diseases
o Ophthalmology
o Gastrointestinal Disorders
o Hormonal Disorders
o Hematological Disorders
o Others
• Pharmaceutical
o API/Bulk Drugs
o Advanced drug delivery formulations
o Packaging
o Finished dose formulations
o Solid
o Liquid
o Semi-solid formulations
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Medical Device Companies
• Pharmaceutical & Biopharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o UAE
o Saudi Arabia
o Kuwait
o Qatar
o Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. End-Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Healthcare Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Expanding Biologics And Biosimilars Market
3.2.1.2. Increasing Regulatory Complexity
3.2.1.3. Commercial Success Of Biologics For Clinical Use
3.2.1.4. Commercial Success Of Biologics For Clinical Use
3.2.2. Market Restraint Analysis
3.2.2.1. Threat Of Information Loss
3.2.2.2. Regulatory And Legal Compliance
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Healthcare Contract Manufacturing Market: Type Estimates & Trend Analysis
4.1. Healthcare Contract Manufacturing Market, By Type: Segment Dashboard
4.2. Healthcare Contract Manufacturing Market, By Type: Movement Analysis
4.3. Healthcare Contract Manufacturing Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. Medical Devices
4.4.1. Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Service
4.4.2.1. Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.2. Accessories manufacturing
4.4.2.2.1. Accessories manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.3. Assembly manufacturing
4.4.2.3.1. Assembly manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.4. Component manufacturing
4.4.2.4.1. Component manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.5. Device manufacturing
4.4.2.5.1. Device manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Therapeutic Area
4.4.3.1. Therapeutic Area Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.2. Oncology
4.4.3.2.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.3. Infectious Diseases
4.4.3.3.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.4. Neurological Disorders
4.4.3.4.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.5. Cardiovascular Disease
4.4.3.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.6. Metabolic Disorders
4.4.3.6.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.7. Autoimmune Diseases
4.4.3.7.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.8. Respiratory Diseases
4.4.3.8.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.9. Ophthalmology
4.4.3.9.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.10. Gastrointestinal Disorders
4.4.3.10.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.11. Hormonal Disorders
4.4.3.11.1. Hormonal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.12. Hematological Disorders
4.4.3.12.1. Hematological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.13. Others
4.4.3.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Pharmaceutical
4.5.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. API/Bulk Drugs
4.5.2.1. API/Bulk Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Advanced drug delivery formulations
4.5.3.1. Advanced drug delivery formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Packaging
4.5.4.1. Packaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5. Finished dose formulations
4.5.5.1. Finished dose formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5.2. Solid
4.5.5.2.1. Solid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5.3. Liquid
4.5.5.3.1. Liquid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5.4. Semi-solid formulations
4.5.5.4.1. Semi-solid formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Healthcare Contract Manufacturing Market: End Use Estimates & Trend Analysis
5.1. Healthcare Contract Manufacturing Market, By End Use: Segment Dashboard
5.2. Healthcare Contract Manufacturing Market, By End Use: Movement Analysis
5.3. Healthcare Contract Manufacturing Market Estimates & Forecasts, By End-Use, 2021 - 2033 (USD Million)
5.4. Medical Device Companies
5.4.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Pharmaceutical & Biopharmaceutical Companies
5.5.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Others
5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Healthcare Contract Manufacturing Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2033
6.3. North America
6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. U.S
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.4. Mexico
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Europe
6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Latin America
6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. Argentina
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. MEA
6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. UAE
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.4. Saudi Arabia
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.6. Qatar
6.7.6.1. Key Country Dynamics
6.7.6.2. Competitive Scenario
6.7.6.3. Regulatory Framework
6.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.7. Oman
6.7.7.1. Key Country Dynamics
6.7.7.2. Competitive Scenario
6.7.7.3. Regulatory Framework
6.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Key Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
7.3. Company Profiles
7.3.1. Nordson Corporation
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Integer Holdings Corporation
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Jabil Inc.
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Viant Technology LLC
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. FLEX LTD.
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Celestica Inc
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Sanmina Corporation
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Plexus Corp
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Phillips-Medisize
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. West Pharmaceutical Services, Inc.
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Synecco Ltd
7.3.11.1. Company Overview
7.3.11.2. Financial Performance
7.3.11.3. Service Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. Catalent, Inc.
7.3.12.1. Company Overview
7.3.12.2. Financial Performance
7.3.12.3. Service Benchmarking
7.3.12.4. Strategic Initiatives
7.3.13. Thermo Fisher Scientific Inc.
7.3.13.1. Company Overview
7.3.13.2. Financial Performance
7.3.13.3. Service Benchmarking
7.3.13.4. Strategic Initiatives
7.3.14. Recipharm AB
7.3.14.1. Company Overview
7.3.14.2. Financial Performance
7.3.14.3. Service Benchmarking
7.3.14.4. Strategic Initiatives
7.3.15. Boehringer Ingelheim International GmbH
7.3.15.1. Company Overview
7.3.15.2. Financial Performance
7.3.15.3. Service Benchmarking
7.3.15.4. Strategic Initiatives
7.3.16. Lonza
7.3.16.1. Company Overview
7.3.16.2. Financial Performance
7.3.16.3. Service Benchmarking
7.3.16.4. Strategic Initiatives
7.3.17. Samsung Biologics
7.3.17.1. Company Overview
7.3.17.2. Financial Performance
7.3.17.3. Service Benchmarking
7.3.17.4. Strategic Initiatives
7.3.18. WuXi AppTec
7.3.18.1. Company Overview
7.3.18.2. Financial Performance
7.3.18.3. Service Benchmarking
7.3.18.4. Strategic Initiatives
7.3.19. FUJIFILM Diosynth Biotechnologies
7.3.19.1. Company Overview
7.3.19.2. Financial Performance
7.3.19.3. Service Benchmarking
7.3.19.4. Strategic Initiatives
7.3.20. Cambrex Corporation
7.3.20.1. Company Overview
7.3.20.2. Financial Performance
7.3.20.3. Service Benchmarking
7.3.20.4. Strategic Initiatives